908 Devices Inc. (MASS) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$10.81

From 52W high−5.14%

Volume854383.00

Market cap$435.24M

P/E (TTM)—

P/S (TTM)7.2x

Div yield—

Key dataSep 18, 2026

Open

$10.81

From 52W high

−5.14%

Volume

854383.00

Market cap

$435.24M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−11.4x

P/E (TTM)

—

RSI (14)

55.9

MomentumView details →

1D Return

−4.10%

YTD Return

+97.71%

SummaryUpdated Jun 1, 2026

908 Devices Inc. (NASDAQ:MASS) is a commercial-stage technology company founded in 2012 and headquartered in Boston, Massachusetts. The company specializes in developing and manufacturing portable mass spectrometry and analytical devices for chemical detection and analysis. Since going public in December 2020, 908 Devices has focused on serving markets including life sciences research, bioprocessing, forensics, and industrial applications with its handheld and desktop analytical instruments.

Ask drillr about 908 Devices Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−11.4x

EV/Sales

5.6x

P/S (TTM)

7.2x

P/B (TTM)

3.4x

ProfitabilityView details →

Gross Margin

49.79%

Net Margin

−56.68%

EBITDA Margin

−48.92%

ROE (TTM)

−27.20%

ROA (TTM)

−17.46%

Asset Turnover

0.32x

GrowthView details →

Revenue YoY

+4.62%

EPS YoY

−69.09%

FCF YoY

+101.69%

Revenue CAGR 3Y

+6.25%

EPS CAGR 3Y

+52.36%

EBITDA YoY

−4.88%

MomentumView details →

1D Return

−4.10%

YTD Return

+97.71%

1Y Return

+42.19%

RSI (14)

55.9

vs 50D SMA

+13.21%

vs 200D SMA

+39.23%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

2.67x

Quick Ratio

2.38x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.11

EPS Surprise

22.54%

Beats (12Q)

7/12

Next Q EPS Est

−$0.16

Avg Surprise (4Q)

0.28%

Rev Surprise

4.55%

Financials snapshotView financials →

Revenue (TTM)

60.84M

Net Income (TTM)

−34.48M

Op. CF (TTM)

1.37M

Next earningsNov 9, 2026 →

Latest newsMore news →

908 Devices reported Q2 2026 revenue of $16.1 million, up 23% year over year, with adjusted EBITDA loss improving by 50%.25d ago

908 Devices Inc. reported financial results for the quarter ended June 30, 2026, with revenue growing 23% year-over-year and Adjusted EBITDA loss narrowing by more than half compared to a year ago.40d ago

Similar companies

Vincent Medical Holdings Limited01612.HK Sight Sciences, Inc.SGHT Pacific Biosciences of California, Inc.PACB ClearPoint Neuro, Inc.CLPT Venus Medtech (Hangzhou) Inc.02500.HK Cryofocus Medtech (Shanghai) Co. Ltd.06922.HK Find similar companies →

Latest newsMore news →

908 Devices reported Q2 2026 revenue of $16.1 million, up 23% year over year, with adjusted EBITDA loss improving by 50%.25d ago 908 Devices Inc. reported financial results for the quarter ended June 30, 2026, with revenue growing 23% year-over-year and Adjusted EBITDA loss narrowing by more than half compared to a year ago.40d ago